Palvella Therapeutics, Inc..
PVLA.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Palvella Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare, genetically defined dermatologic diseases with no approved treatments. Their lead product candidate is PTX-022 (QTORIN™ rapamycin topical formulation) for the treatment of pachyon...Show More
Better Health for All
0
No evidence available to assess Palvella Therapeutics, Inc. on Better Health for All.
Fair Money & Economic Opportunity
0
No evidence available to assess Palvella Therapeutics, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No evidence available to assess Palvella Therapeutics, Inc. on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
No evidence available to assess Palvella Therapeutics, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-20
Palvella Therapeutics has a Corporate Code of Ethics and Conduct and a Whistleblower Policy, which is posted on its website and available to stockholders.
1
The Audit Committee is responsible for establishing procedures for employees to anonymously submit concerns about questionable accounting or audit matters.
2
A confidential and anonymous financial concern hotline is established, accessible 24/7 via a toll-free number and web-based service, managed by an independent third-party, with concerns referred to the Audit Committee chair.
3
The company had one financial restatement in the past five years, specifically an amendment to its 2014 10-K filing that restated certain items but did not modify financial or other information.
4
The Board of Directors has determined that 7 out of 8 members are independent, with the CEO being the non-independent director.
5
The company's Code of Conduct addresses bribery and kickbacks, and the Nominating and Corporate Governance Committee oversees compliance with this code.
6
The company's financial statements are audited by Ernst & Young LLP, an independent registered public accounting firm, and the whistleblower hotline is managed by an independent third-party.
7
Kind to Animals
0
No specific evidence was found in the provided articles regarding Palvella Therapeutics, Inc.'s (PVLA.US) performance against any of the 'Kind to Animals' KPIs. The articles primarily discuss general industry trends, regulatory changes (like the FDA Modernization Act), and overall statistics on animal testing, rather than specific actions, policies, or metrics attributable to PVLA.US.
1
No War, No Weapons
0
No evidence available to assess Palvella Therapeutics, Inc. on No War, No Weapons.
Planet-Friendly Business
0
No evidence available to assess Palvella Therapeutics, Inc. on Planet-Friendly Business.
Respect for Cultures & Communities
0
The provided articles focus on Palvella Therapeutics' clinical studies and drug development for rare genetic skin diseases. No information is available regarding the company's engagement with local or indigenous communities, cultural impact assessments, community investments, employment practices, grievance mechanisms, or any other metrics related to Respect for Cultures & Communities.
1
Articles 4 and 5 were inaccessible due to throttling errors.
2
Safe & Smart Tech
0
No specific, concrete evidence was found across the provided articles for any of the 'Safe & Smart Tech' KPIs. The articles primarily focus on the company's drug development, clinical trials, and intellectual property, with limited information on its data protection, cybersecurity, or AI ethics practices. While a privacy policy was mentioned, it did not contain quantifiable data points relevant to the specific KPIs, nor did it detail the implementation or effectiveness of privacy-by-design principles, data minimization, or regulatory compliance beyond general statements.
1
A reporting hotline was noted, but it was not explicitly defined as a vulnerability disclosure or bug bounty program, and therefore could not be used as evidence for that KPI.
2
Zero Waste & Sustainable Products
0
No specific, concrete data points related to waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education were found in the provided articles.
1